Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial

Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial
Receptos, Inc. a biopharmaceutical company that develops drug candidates for the treatment of immune and metabolic diseases, recently announced positive results for the maintenance period of TOUCHSTONE, a Phase 2 clinical study examining the efficacy of ozanimod (previously known as RPC1063) for the treatment of ulcerative colitis (UC). According to a recent news release, after 32

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *